VNRX - VolitionRx Limited

NYSE American - Nasdaq Real Time Price. Currency in USD
3.16
-0.09 (-2.74%)
As of 1:06PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close3.25
Open3.25
Bid3.16 x 200
Ask3.20 x 100
Day's Range3.16 - 3.30
52 Week Range2.08 - 4.71
Volume8,021
Avg. Volume82,944
Market Cap83.826M
Beta-0.01
PE Ratio (TTM)N/A
EPS (TTM)-0.52
Earnings DateMar 8, 2018 - Mar 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.67
Trade prices are not sourced from all markets
  • PR Newswire16 days ago

    VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.

    ISNES, Belgium, Feb. 5, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the successful conclusion to the Logistics and Pathway Design Study conducted by Hvidovre Hospital and The Danish Research Group.  The study was established to answer the very practical, logistical questions of how a triage blood test could fit into the current Danish screening program for colorectal cancer ("CRC"). The study showed that it was indeed possible to collect, process, gather and ship the blood test from all five participating hospitals to a central laboratory within 24 hours. Furthermore, analysis from the central laboratory was shown to provide the needed data in due time (in accordance with current Danish Legislation) to decide whether or not to perform a colonoscopy.

  • PR Newswire2 months ago

    VolitionRx Limited Releases Letter to Shareholders Including Status Update on Key Clinical Milestone

    ISNES, Belgium, Jan. 3, 2018 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today released an important letter from Group CEO, Cameron Reynolds updating the company's shareholders. In the letter, Mr. Reynolds outlines several significant accomplishments to date and highlights the fact that the company believes that it is close to achieving a key clinical milestone with the completion of a 680-subject trial for the Nu.QTM Frontline Asymptomatic Colorectal Cancer Screening Test. Volition expects to report the results from this study in early February.

  • PR Newswire3 months ago

    VolitionRx Limited to Attend Conferences in December

    ISNES, Belgium , Dec. 5, 2017 /PRNewswire/ --  VolitionRx Limited  (NYSE American: VNRX) today announced that its Executive Vice President, Scott Powell , is scheduled to attend two conferences in December. ...

  • Zacks Small Cap Research3 months ago

    VNRX: Frontline CRC Studies Read-Out ~1H 2018, Could Be Value-Inflection Event

    By Brian Marckx, CFA NYSE:VNRX Q3 Results / Operational and Business Update:  VolitionRx (NYSE:VNRX) reported Q3 results and provided a business update.  Relative to the financials, results were very much ...

  • PR Newswire3 months ago

    Singapore Volition signs Memorandum of Understanding with the National Taiwan University to Conduct Two Large Clinical Studies

    ISNES, Belgium, Nov. 10, 2017 /PRNewswire/ -- Singapore Volition Pte. Ltd, a wholly-owned subsidiary of VolitionRx Limited (NYSE American: VNRX) ("Volition"), has entered into a Memorandum of Understanding ("MOU") with the National Taiwan University ("NTU") to conduct two large colorectal cancer (CRC) research studies across the Asia Pacific Region, totaling approximately 7,000 patient samples. "The signing of this MOU is a good start for Volition in the Asia Pacific Region" commented Dr. Jasmine Kway, Volition's Vice President of Asia. "We are fortunate and delighted to be working with a renowned institution and Professor Han-Mo Chiu, a prominent thought leader. The first trial will be a large scale multi-country, multi-center and multi-ethnic study in the Asia Pacific Region, including 5,000 asymptomatic colorectal cancer screening subjects.

  • ACCESSWIRE3 months ago

    Volitionrx Limited to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / November 10, 2017 / Volitionrx Limited (NYSE: VNRX ) will be discussing their earnings results in their Q3 Earnings Call to be held on Friday, November 10, 2017 at 8:30 AM Eastern ...

  • What Investors Should Know About VolitionRx Limited’s (VNRX) Financial Strength
    Simply Wall St.3 months ago

    What Investors Should Know About VolitionRx Limited’s (VNRX) Financial Strength

    Investors are always looking for growth in small-cap stocks like VolitionRx Limited (AMEX:VNRX), with a market cap of USD $78.23M. However, an important fact which most ignore is: how financiallyRead More...

  • Associated Press3 months ago

    VolitionRX reports 3Q loss

    On a per-share basis, the Singapore-based company said it had a loss of 15 cents. In the final minutes of trading on Thursday, the company's shares hit $3.12. A year ago, they were trading at $4.40. _____ ...

  • PR Newswire3 months ago

    VolitionRx Limited Announces Third Quarter 2017 Financial Results and Business Update

    ISNES, Belgium, Nov. 9, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced financial results and a business update for the third quarter ended September 30, 2017. Volition management will host a conference call tomorrow, November 10, at 8:30 a.m. U.S. Eastern Time to discuss these results. Mr. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "We have made fantastic progress this quarter, moving our clinical product development strongly forward in Asia, Europe and the U.S, and broadening our potential revenue base with our recently announced research kit sales.

  • PR Newswire5 months ago

    VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits

    ISNES, Belgium, Sept. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its strategy for a new range of Clinical Research Use Only (RUO) kits based on its proprietary Nucleosomics™ technology and the receipt of an order of RUO kits from a large multinational pharmaceutical company. Chief Executive Officer of Volition, Cameron Reynolds, commented, "This is a very important milestone for Volition as it represents our first revenue from the Nu.Q™ platform. The RUO kits could be used to develop a companion diagnostic to a pharmaceutical company's therapeutic product, so could represent an additional potential revenue stream beyond the commercialization of our blood-based cancer tests on the same platform of assays.

  • PR Newswire5 months ago

    VolitionRx Limited Awarded $1.5 Million in Non-Dilutive Funding

    ISNES, Belgium, Sept. 21, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded a loan and a non-repayable grant totaling $1.5 million from SOFINEX and the Walloon Region, Belgium. Dr. Gaetan Michel, Chief Executive Officer of Volition's subsidiary, Belgian Volition SPRL, commented, "We are delighted with the financial support that we continue to receive from our local agencies SOFINEX and Namur Invest, as well as the Walloon Region, Belgium.

  • PR Newswire5 months ago

    VolitionRx Announces its European Colorectal Cancer Strategy

    ISNES, Belgium, Sept. 19, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced its colorectal cancer (CRC) strategy for Europe.  As part of its strategy, Volition plans to select a frontline panel to be validated in two large trials (4,300 and 10,000 sample), followed by CE marking, with a goal to launch a European frontline CRC screening product in 2018. Chief Executive Officer of Volition, Cameron Reynolds, commented, "We believe that the market for the frontline screening test represents the largest near-term opportunity for Volition, as there are 150 million Europeans of screening age. "We are making significant progress with our frontline CRC screening test," said Dr. Gaetan Michel, Chief Executive Officer of Belgian Volition.

  • PR Newswire5 months ago

    VolitionRx to Attend Two Major Conferences in Asia

    Volition's Vice President of Asia, Dr. Jasmine Kway, commented, "Asia is a very important market for Volition and we have made significant progress in the region since January of this year. There is a growing aging population in many countries in Asia, with more than 40% of worldwide colorectal cancers occurring there. Volition has been developing its position in Asia since the beginning of 2017 and has generated encouraging responses from key opinion leaders (KOLs) in the region.

  • PR Newswire5 months ago

    Volition Granted Four Additional Patents

    ISNES, Belgium, Sept. 14, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been granted four additional patents relating to its proprietary Nu.QTM platform. The newly-issued patents further strengthen Volition's intellectual property portfolio worldwide. Dr. Jake Micallef, Chief Scientific Officer of Volition, commented, "Our worldwide portfolio of granted patents that protects various aspects of Volition's Nu.QTM technology is growing. Cameron Reynolds, Chief Executive Officer of Volition, added, "The granting of these patents is excellent news.

  • Marketwired5 months ago

    GVC Capital and Trickle Research Announce Preliminary Presenter Schedule for Inaugural Rocky Mountain MicroCap Conference in Denver on September 25, 2017

    GVC Capital LLC and Dave Lavigne at Trickle Research LLC will host the inaugural Rocky Mountain MicroCap Conference on September 25, 2017, in Denver at Coors Field. The Rocky Mountain MicroCap Conference ...

  • PR Newswire6 months ago

    VolitionRx Limited to Attend Multiple Conferences in September

    ISNES, Belgium , Sept. 6, 2017 /PRNewswire/ --  VolitionRx Limited  (NYSE American: VNRX) today announced that its Chief Executive Officer, Cameron Reynolds , its Executive Vice President, Scott Powell ...

  • Zacks Small Cap Research6 months ago

    VNRX: Pathway Design Study Progressing. Expect European Launch in 2018

    VolitionRx (VNRX) reported Q2 results and provided an operational update.  Relative to the financials, the $3.5M in operating expenses were inline with our $3.6M estimate.  We continue to model only incremental growth in operating expenses through the remainder of 2017, despite expectations of additional development and pre-commercialization activities including those related to the Triage reconfiguration and CE Mark updating as well as completion of the pathway design study in Denmark.  We continue to model no revenue until 2018.

  • PR Newswire6 months ago

    Volition Signs Agreement with the Institute of Laboratory Medicine of the Technical University of Munich, Germany, to assist in securing large trials in a range of cancers

    ISNES, Belgium, Aug. 22, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) today announced a three-year agreement to work with the renowned expert Professor Stefan Holdenrieder at the Institute of Laboratory Medicine of the German Heart Center at the Technical University of Munich, Germany. Professor Holdenrieder is the Director of the Institute of Laboratory Medicine and will be the principal investigator on Volition's nucleosome projects, aided by several members of his team. Professor Holdenrieder is an expert in the field of circulating nucleosomes and is widely published.

  • Associated Press6 months ago

    VolitionRX reports 2Q loss

    On a per-share basis, the Singapore-based company said it had a loss of 13 cents. The company's shares closed at $2.86. A year ago, they were trading at $3.31. _____ This story was generated by Automated ...

  • PR Newswire6 months ago

    VolitionRx Limited Announces Second Quarter 2017 Financial Results and Business Update

    ISNES, Belgium, Aug. 9, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the quarter ended June 30, 2017. Volition management will host a conference call to discuss these results and provide a further business update tomorrow, August 10, 2017 at 8:30 AM U.S. Eastern Time. Cameron Reynolds, President and Chief Executive Officer of Volition, said, "We have had numerous highlights this quarter, with strong progress being made on many fronts.

  • PR Newswire7 months ago

    VolitionRx Limited Schedules Second Quarter 2017 Earnings Conference Call and Business Update

    Conference call to take place Thursday, August 10, 2017 at 8:30 am Eastern time ISNES, Belgium , Aug. 3, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) today announced it will host a conference ...

  • Zacks Small Cap Research7 months ago

    VNRX: Large U.S. Study Comes Cheap, Could Support Asymptomatic FDA Filing

    VNRX is required to contribute just $3M (paid in equal quarterly installments over 3 years), with most of the funding borne by the study's main sponsor, the U.S. National Cancer Institute's (NCI) Early Detection Network (EDRN), which is the leading cancer research organization in the U.S.  The Great Lakes New England Clinical Validation Center and the University of Michigan are also major participants and, along with EDRN, focused on the pursuit of technologies for the early detection of cancer. • will include ~13.5k asymptomatic screening samples from subjects 50 years of age who have not previously undergone colonoscopy or CRC screening.

  • PR Newswire7 months ago

    VolitionRx Limited to host a conference call regarding a 13,500 Subject Colorectal Cancer Screening Trial with the Early Detection Research Network of the U.S. National Cancer Institute

    NYSE MKT: VNRX), announced it will host a conference call tomorrow, July 20 at 8:30 AM U.S. Eastern Time to discuss its participation in a large multi-center clinical study with the Great Lakes New England Clinical Validation Center funded by the U.S. National Cancer Institute's (NCI) Early Detection Research Network (EDRN) in addition to providing a business update. Volition will host a conference call on Thursday July 20 at 8:30 AM U.S. Eastern Time to further discuss the participation in this clinical study in addition to providing a business update. The call will be hosted by Cameron Reynolds along with Jason Terrell.

  • PR Newswire7 months ago

    Volition America, Inc. Announces a Colorectal Cancer Screening Trial containing approximately 13,500 Subjects in Collaboration with the Early Detection Research Network of the U.S. National Cancer Institute

    NYSE MKT: VNRX), has signed an agreement to participate in a large multi-center clinical study with the Great Lakes New England Clinical Validation Center funded by the U.S. National Cancer Institute's (NCI) Early Detection Research Network (EDRN). The clinical study will provide approximately 13,500 asymptomatic screening samples of people aged 50 or over who have not previously undergone screening or a diagnostic colonoscopy. The aim of the trial will be to validate a panel of biomarkers that include Volition's Nu.Q™ Colorectal Cancer Screening Test in a large asymptomatic population to support U.S. regulatory approval.

  • PR Newswire8 months ago

    Volition to Present at the EuropaColon Advocacy Masterclass and Exhibit at the European Society for Medical Oncology Gastrointestinal Cancer Congress

    ISNES, Belgium, June 30, 2017 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX) today announced it will be presenting at the EuropaColon Advocacy Masterclass and will be exhibiting at the European Society for Medical Oncology Congress on Gastrointestinal Cancer (ESMO GI). The organisation's annual Advocacy Masterclass will be held in Barcelona, Spain from Thursday 29th June till Saturday 1st July, in partnership with ESMO GI.  On Friday 30th June, Volition's Chief Scientific Officer, Dr. Jake Micallef, will present a talk at the masterclass entitled 'The future of screening'. ESMO GI is a global event related to the care of patients with gastrointestinal cancer.